Christopher Hatwig | President
Apexus

Christopher Hatwig, President, Apexus

Christopher A. Hatwig, MS, RPh, FASHP, is President of Apexus and a nationally recognized healthcare executive and expert in the 340B Drug Pricing Program, specialty pharmacy, and medication access. He leads Apexus in its role as HRSA’s contracted 340B Prime Vendor and in developing innovative solutions that support 340B stakeholders and the patients they serve. Hatwig is a frequent national speaker and trusted resource on 340B policy, drug pricing, program integrity, specialty pharmacy, and healthcare economics. Prior to Apexus, he held progressive leadership roles in pharmacy, purchasing, and value analysis at Parkland Health & Hospital System. He is a Fellow of ASHP and holds degrees from the University of Wisconsin–Madison, University of Arkansas for Medical Sciences, and Hendrix College.

Appearances:



Day One @ 15:10

Reforming 340B: What Can Be Done to Regain Program Integrity?

  • Current status of the 340B rebate pilot (beginning Jan 2027)
  • How do we improve transparency into the ways hospitals are using 340B revenue?
  • How can we ensure patients are feeling the benefit?
  • The role of manufacturers and pharmacies in ensuring program integrity is maintained? (Avoiding duplicate discounts, increasing transparency in claims data submissions)
  • Are there any supply chain implications?
last published: 08/Sep/26 08:20 GMT

back to speakers

Get Involved 
 

Sponsorship & Exhibition Sales


Steph Scanlon Steph.scanlon@terrapinn.com

 

Speaking Opportunities


Charlie Humphrey
Charlie.humphrey@terrapinn.com
 

Marketing Opportunities


Hidy Lee
hidy.lee@terrapinn.com